Abstract
Background: The efficacy of tolvaptan, a vasopressin V2 antagonist, in heart failure (HF) patients with volume overload has been shown in the QUEST trial. We conducted further sub-group analyses by patient backgrounds. Method and Result: The change in body weight from the baseline, the primary endpoint, was analyzed with stratification by patient backgrounds. The type of concomitant diuretics, type of basic therapy for the heart failure, and dosage of furosemide did not affect the amount of decrease in body weight following 7-day treatment with tolvaptan at 15 mg/day.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
